FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013411992> ?p ?o ?g. }

• W2013411992 endingPage "2370" @default.
• W2013411992 startingPage "2358" @default.
• W2013411992 abstract "Background. Interleukin-2 (IL-2), used alone or in combination with adoptive cellular therapy, is one of the most promising biologic therapeutic agents for cancer treatment. Methods. The National Biotherapy Study Group conducted 15 trials of continuous-infusion IL-2 involving 788 patients with cancer, 638 of whom were evaluable for tumor response. The protocols included administration of IL-2 and lymphokine-activated killer (LAK) cells, IL-2 and cyclophosphamide, IL-2 and tumor-infiltrating lymphocytes, IL-2 and alpha-interferon (IFN), IL-2 and tumor necrosis factor, and IL-2 and LAK alternating with combination chemotherapy. Results. Responses were detected in 33 of 188 patients (18%) with melanomas, 13 of 167 (8%) with renal cell carcinomas, and 1 of 76 (1%) with colorectal cancers. The median survival times in patients with melanoma and renal cell cancer were 9.6 and 9.3 months, respectively. The proportion of patients surviving 1 year were 35% and 43%, respectively. There were responses in 8 of 51 patients (16%) with lung cancer, but many of these patients received IL-2 and LAK alternating with platinum-based chemotherapy. Four of 23 patients (17%) responded who had breast cancer and received IL-2 and IFN. The protocols involving IL-2 plus adoptive cellular therapy produced a higher response rate than those not involving activated cells (48 of 312 [15%] versus 24 of 326 [7%], P = 0.003); however, there was no difference in survival. There was a 1.8% mortality rate attributed to the complications of IL-2 itself. Conclusions. IL-2 produces durable tumor responses in some patients, especially in those with melanoma and renal cell carcinoma. Because the drug's toxicity is significant and the overall response rates are low, patient selection may be the most important factor in the clinical use of continuous-infusion IL-2 therapy." @default.
• W2013411992 created "2016-06-24" @default.
• W2013411992 creator A5038399837 @default.
• W2013411992 creator A5041060500 @default.
• W2013411992 creator A5054029208 @default.
• W2013411992 creator A5065177684 @default.
• W2013411992 creator A5072563567 @default.
• W2013411992 creator A5085906072 @default.
• W2013411992 date "1993-04-01" @default.
• W2013411992 modified "2023-09-27" @default.
• W2013411992 title "Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience" @default.
• W2013411992 cites W1884121283 @default.
• W2013411992 cites W1904436785 @default.
• W2013411992 cites W1915622915 @default.
• W2013411992 cites W1966196375 @default.
• W2013411992 cites W1975568557 @default.
• W2013411992 cites W1978350435 @default.
• W2013411992 cites W1982838179 @default.
• W2013411992 cites W1993051112 @default.
• W2013411992 cites W2007872459 @default.
• W2013411992 cites W2022771239 @default.
• W2013411992 cites W2065393730 @default.
• W2013411992 cites W2067925808 @default.
• W2013411992 cites W2082162853 @default.
• W2013411992 cites W2083558626 @default.
• W2013411992 cites W2087897460 @default.
• W2013411992 cites W2094619261 @default.
• W2013411992 cites W2108117103 @default.
• W2013411992 cites W2149724818 @default.
• W2013411992 cites W2160806636 @default.
• W2013411992 cites W2178727026 @default.
• W2013411992 cites W2222964685 @default.
• W2013411992 cites W2270697554 @default.
• W2013411992 cites W2273122936 @default.
• W2013411992 cites W2320058521 @default.
• W2013411992 cites W2322553446 @default.
• W2013411992 cites W2326245275 @default.
• W2013411992 cites W2399766730 @default.
• W2013411992 cites W4293241248 @default.
• W2013411992 doi "https://doi.org/10.1002/1097-0142(19930401)71:7<2358::aid-cncr2820710730>3.0.co;2-m" @default.
• W2013411992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8453558" @default.
• W2013411992 hasPublicationYear "1993" @default.
• W2013411992 type Work @default.
• W2013411992 sameAs 2013411992 @default.
• W2013411992 citedByCount "129" @default.
• W2013411992 countsByYear W20134119922012 @default.
• W2013411992 countsByYear W20134119922014 @default.
• W2013411992 countsByYear W20134119922015 @default.
• W2013411992 countsByYear W20134119922017 @default.
• W2013411992 countsByYear W20134119922018 @default.
• W2013411992 countsByYear W20134119922020 @default.
• W2013411992 crossrefType "journal-article" @default.
• W2013411992 hasAuthorship W2013411992A5038399837 @default.
• W2013411992 hasAuthorship W2013411992A5041060500 @default.
• W2013411992 hasAuthorship W2013411992A5054029208 @default.
• W2013411992 hasAuthorship W2013411992A5065177684 @default.
• W2013411992 hasAuthorship W2013411992A5072563567 @default.
• W2013411992 hasAuthorship W2013411992A5085906072 @default.
• W2013411992 hasBestOaLocation W20134119921 @default.
• W2013411992 hasConcept C121608353 @default.
• W2013411992 hasConcept C126322002 @default.
• W2013411992 hasConcept C129374314 @default.
• W2013411992 hasConcept C143998085 @default.
• W2013411992 hasConcept C203014093 @default.
• W2013411992 hasConcept C2776090121 @default.
• W2013411992 hasConcept C2776256026 @default.
• W2013411992 hasConcept C2776694085 @default.
• W2013411992 hasConcept C2776755627 @default.
• W2013411992 hasConcept C2777371288 @default.
• W2013411992 hasConcept C2777658100 @default.
• W2013411992 hasConcept C2777701055 @default.
• W2013411992 hasConcept C2778326572 @default.
• W2013411992 hasConcept C2778690821 @default.
• W2013411992 hasConcept C28651165 @default.
• W2013411992 hasConcept C502942594 @default.
• W2013411992 hasConcept C526805850 @default.
• W2013411992 hasConcept C71924100 @default.
• W2013411992 hasConcept C8891405 @default.
• W2013411992 hasConcept C90924648 @default.
• W2013411992 hasConceptScore W2013411992C121608353 @default.
• W2013411992 hasConceptScore W2013411992C126322002 @default.
• W2013411992 hasConceptScore W2013411992C129374314 @default.
• W2013411992 hasConceptScore W2013411992C143998085 @default.
• W2013411992 hasConceptScore W2013411992C203014093 @default.
• W2013411992 hasConceptScore W2013411992C2776090121 @default.
• W2013411992 hasConceptScore W2013411992C2776256026 @default.
• W2013411992 hasConceptScore W2013411992C2776694085 @default.
• W2013411992 hasConceptScore W2013411992C2776755627 @default.
• W2013411992 hasConceptScore W2013411992C2777371288 @default.
• W2013411992 hasConceptScore W2013411992C2777658100 @default.
• W2013411992 hasConceptScore W2013411992C2777701055 @default.
• W2013411992 hasConceptScore W2013411992C2778326572 @default.
• W2013411992 hasConceptScore W2013411992C2778690821 @default.
• W2013411992 hasConceptScore W2013411992C28651165 @default.
• W2013411992 hasConceptScore W2013411992C502942594 @default.
• W2013411992 hasConceptScore W2013411992C526805850 @default.
• W2013411992 hasConceptScore W2013411992C71924100 @default.
• W2013411992 hasConceptScore W2013411992C8891405 @default.

• next